Key clinical point: Despite failing to best current chemotherapies for relapsed/refractory peripheral T-cell lymphoma, a new report suggests that alisertib might have a role as a last-ditch option.
Major finding: Overall response rate (ORR) was 33% for alisertib versus 45% for the comparator arm (odds ratio, 0.60; 95% confidence interval, 0.33-1.08).
Study details: Open-label trial in 271 relapsed/refractory PTCL patients.
Disclosures: The work was funded by alisertib maker Millennium Pharmaceuticals, a subsidiary of Takeda. Investigators reported various ties to Millennium and Takeda, including research funding, honoraria, and consulting work. The study team included employees of those companies.
This Week's Must Reads
Must Reads in Lymphoma & Plasma Cell Disorders
Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9